LU92238I9 - - Google Patents
Info
- Publication number
- LU92238I9 LU92238I9 LU92238C LU92238C LU92238I9 LU 92238 I9 LU92238 I9 LU 92238I9 LU 92238 C LU92238 C LU 92238C LU 92238 C LU92238 C LU 92238C LU 92238 I9 LU92238 I9 LU 92238I9
- Authority
- LU
- Luxembourg
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Psychology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41759002P | 2002-10-10 | 2002-10-10 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LU92238I2 LU92238I2 (fr) | 2013-09-03 |
| LU92238I9 true LU92238I9 (fr) | 2019-01-09 |
Family
ID=32094042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU92238C LU92238I2 (fr) | 2002-10-10 | 2013-07-03 | 1-(4-Chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one ou l'un de sls physiologiquement acceptables. autre formulation du composé chimiqu e:1-(4-Chlorophenyl)4-morpholino-imidazolin-2-one |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US20050070537A1 (fr) |
| EP (3) | EP2845594B1 (fr) |
| JP (4) | JP4694202B2 (fr) |
| KR (2) | KR20110063843A (fr) |
| CN (2) | CN1726040B (fr) |
| AR (1) | AR041573A1 (fr) |
| AT (1) | ATE418337T1 (fr) |
| AU (2) | AU2003273978B2 (fr) |
| BE (1) | BE2013C046I2 (fr) |
| BR (1) | BR0315225A (fr) |
| CA (2) | CA2727722C (fr) |
| CY (3) | CY1109961T1 (fr) |
| DE (1) | DE60325496D1 (fr) |
| DK (2) | DK2845594T3 (fr) |
| ES (2) | ES2908453T3 (fr) |
| FR (2) | FR13C0044I2 (fr) |
| HK (1) | HK1085920A1 (fr) |
| HR (3) | HRP20090667B1 (fr) |
| HU (2) | HUS1300035I1 (fr) |
| LU (1) | LU92238I2 (fr) |
| MX (1) | MXPA05003663A (fr) |
| NZ (1) | NZ539864A (fr) |
| PL (2) | PL214702B1 (fr) |
| PT (2) | PT1553952E (fr) |
| SI (2) | SI1553952T1 (fr) |
| TW (2) | TWI324067B (fr) |
| WO (1) | WO2004032938A1 (fr) |
| ZA (1) | ZA200502245B (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050070537A1 (en) * | 2002-10-10 | 2005-03-31 | Chris Rundfeldt | Use of dihydroimidazolones for the treatment of dogs |
| MXPA05013196A (es) * | 2003-07-11 | 2006-03-09 | Elbion Ag | Metodo para tratar o evitar trastornos del sistema nervioso central con compuestos que tienen selectividad por la subunidad alfa 3 del receptor de benzodiazepina. |
| RU2014109074A (ru) | 2011-08-12 | 2015-09-20 | Бёрингер Ингельхайм Ветмедика Гмбх | ИНГИБИТОРЫ ФАННИ-ТОКА (If), ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПРИМЕНЕНИЯ В СПОСОБЕ ЛЕЧЕНИЯ И ПРЕДУПРЕЖДЕНИЯ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ У КОШАЧЬИХ |
| JP6193613B2 (ja) * | 2013-05-10 | 2017-09-06 | 学校法人麻布獣医学園 | てんかん発作のモニタリングシステム及びモニタリング方法 |
| US9820988B2 (en) | 2014-03-24 | 2017-11-21 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of epileptic disorders in feline animals |
| US9856250B2 (en) | 2014-05-28 | 2018-01-02 | Toa Eiyo Ltd. | Substituted tropane derivatives |
| US10117891B2 (en) | 2014-09-16 | 2018-11-06 | India Globalization Capital, Inc. | Cannabinoid composition for treating pain |
| EP3247359A4 (fr) | 2015-01-25 | 2018-08-08 | India Globalization Capital, Inc. | Compositions et procédés de traitement de troubles épileptiques |
| US10596159B2 (en) | 2015-08-12 | 2020-03-24 | India Globalization Capital, Inc. | Method and composition for treating cachexia and eating disorders |
| WO2017218629A1 (fr) | 2016-06-15 | 2017-12-21 | India Globalization Capital, Inc. | Méthode et composition pour traiter des troubles epileptiques |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4044021A (en) | 1971-10-21 | 1977-08-23 | American Cyanamid Company | Tetrasubstituted imidazolidine diuretics useful in the treatment of hyperaldosteronism |
| US3932452A (en) | 1975-02-07 | 1976-01-13 | Morton-Norwich Products, Inc. | 1-Arylmethyl-2-imidazolidinones |
| DE19532668A1 (de) | 1995-09-05 | 1997-03-06 | Dresden Arzneimittel | Neue, antikonvulsiv wirkende 1-Ar(alk)yl-imidazolin-2-one, die in 4-Stellung einen disubstituierten Amin-Rest enthalten, und Verfahren zu deren Herstellung |
| US5869481A (en) | 1995-09-05 | 1999-02-09 | Arzneitmittelwerk Dresden G.M.B.H. | Anticonvulsive 1-ar(alk)ylimidazolin-2-ones and process for making |
| DE19721580A1 (de) * | 1997-05-23 | 1998-11-26 | Dresden Arzneimittel | Verwendung von 1-Ar(alk)yl-imidazolin-2-one zur Behandlung von Angst- und Spannungszuständen |
| AU8168998A (en) * | 1997-06-26 | 1999-01-19 | Board Of Regents, The University Of Texas System | Synthesis of dihydrohonokiol compositions |
| JP4669095B2 (ja) * | 1999-07-19 | 2011-04-13 | 太陽化学株式会社 | ペットの問題行動抑制組成物 |
| EA009664B1 (ru) | 2002-03-07 | 2008-02-28 | Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг | Предназначенная для перорального применения лекарственная форма для этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}-1-метил-1h-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты и его солей |
| US20050070537A1 (en) | 2002-10-10 | 2005-03-31 | Chris Rundfeldt | Use of dihydroimidazolones for the treatment of dogs |
| DE10339862A1 (de) | 2003-08-29 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel |
| RU2014109074A (ru) | 2011-08-12 | 2015-09-20 | Бёрингер Ингельхайм Ветмедика Гмбх | ИНГИБИТОРЫ ФАННИ-ТОКА (If), ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПРИМЕНЕНИЯ В СПОСОБЕ ЛЕЧЕНИЯ И ПРЕДУПРЕЖДЕНИЯ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ У КОШАЧЬИХ |
| US9820988B2 (en) | 2014-03-24 | 2017-11-21 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of epileptic disorders in feline animals |
-
2003
- 2003-10-06 US US10/680,459 patent/US20050070537A1/en not_active Abandoned
- 2003-10-08 TW TW092127976A patent/TWI324067B/zh not_active IP Right Cessation
- 2003-10-08 TW TW098142077A patent/TWI424849B/zh not_active IP Right Cessation
- 2003-10-09 WO PCT/EP2003/011212 patent/WO2004032938A1/fr active Application Filing
- 2003-10-09 DK DK14191084.4T patent/DK2845594T3/da active
- 2003-10-09 PT PT03757945T patent/PT1553952E/pt unknown
- 2003-10-09 CA CA2727722A patent/CA2727722C/fr not_active Expired - Lifetime
- 2003-10-09 HR HRP20090667AA patent/HRP20090667B1/hr not_active IP Right Cessation
- 2003-10-09 JP JP2004542480A patent/JP4694202B2/ja not_active Expired - Lifetime
- 2003-10-09 KR KR1020117009632A patent/KR20110063843A/ko not_active Application Discontinuation
- 2003-10-09 EP EP14191084.4A patent/EP2845594B1/fr not_active Expired - Lifetime
- 2003-10-09 AT AT03757945T patent/ATE418337T1/de active
- 2003-10-09 PL PL374603A patent/PL214702B1/pl unknown
- 2003-10-09 CN CN2003801057558A patent/CN1726040B/zh not_active Expired - Lifetime
- 2003-10-09 KR KR1020057006150A patent/KR101110587B1/ko active Protection Beyond IP Right Term
- 2003-10-09 ES ES14191084T patent/ES2908453T3/es not_active Expired - Lifetime
- 2003-10-09 BR BR0315225-1A patent/BR0315225A/pt active Pending
- 2003-10-09 EP EP03757945A patent/EP1553952B1/fr not_active Expired - Lifetime
- 2003-10-09 CN CN2010101440231A patent/CN101890019A/zh active Pending
- 2003-10-09 SI SI200331504T patent/SI1553952T1/sl unknown
- 2003-10-09 SI SI200332622T patent/SI2845594T1/sl unknown
- 2003-10-09 ES ES03757945T patent/ES2316808T3/es not_active Expired - Lifetime
- 2003-10-09 DE DE60325496T patent/DE60325496D1/de not_active Expired - Lifetime
- 2003-10-09 AR ARP030103685A patent/AR041573A1/es unknown
- 2003-10-09 AU AU2003273978A patent/AU2003273978B2/en not_active Expired
- 2003-10-09 PL PL397320A patent/PL238776B1/pl unknown
- 2003-10-09 DK DK03757945T patent/DK1553952T3/da active
- 2003-10-09 MX MXPA05003663A patent/MXPA05003663A/es active IP Right Grant
- 2003-10-09 CA CA2501772A patent/CA2501772C/fr not_active Expired - Lifetime
- 2003-10-09 EP EP08167818A patent/EP2036563A1/fr not_active Ceased
- 2003-10-09 PT PT141910844T patent/PT2845594T/pt unknown
- 2003-10-09 NZ NZ539864A patent/NZ539864A/en not_active IP Right Cessation
-
2005
- 2005-03-17 ZA ZA2005/02245A patent/ZA200502245B/en unknown
- 2005-04-08 HR HRP20050322AA patent/HRP20050322B1/hr not_active IP Right Cessation
-
2006
- 2006-05-23 HK HK06105907.5A patent/HK1085920A1/xx not_active IP Right Cessation
-
2007
- 2007-07-18 US US11/879,708 patent/US8859540B2/en active Active
-
2009
- 2009-03-20 CY CY20091100314T patent/CY1109961T1/el unknown
- 2009-10-12 AU AU2009225322A patent/AU2009225322A1/en not_active Abandoned
-
2010
- 2010-12-28 JP JP2010293113A patent/JP2011068685A/ja not_active Withdrawn
-
2012
- 2012-09-14 US US13/616,440 patent/US8962617B2/en not_active Expired - Lifetime
-
2013
- 2013-07-03 BE BE2013C046C patent/BE2013C046I2/fr unknown
- 2013-07-03 LU LU92238C patent/LU92238I2/fr unknown
- 2013-07-11 CY CY2013031C patent/CY2013031I1/el unknown
- 2013-07-24 FR FR13C0044C patent/FR13C0044I2/fr active Active
- 2013-07-24 HU HUS1300035C patent/HUS1300035I1/hu unknown
-
2014
- 2014-02-14 JP JP2014026704A patent/JP6249812B2/ja not_active Expired - Lifetime
- 2014-11-17 US US14/542,888 patent/US9469611B2/en not_active Expired - Lifetime
-
2016
- 2016-02-29 JP JP2016038151A patent/JP2016104817A/ja not_active Withdrawn
- 2016-08-30 US US15/251,022 patent/US20160367562A1/en not_active Abandoned
-
2020
- 2020-02-07 HR HRP20200207AA patent/HRP20200207A2/hr not_active Application Discontinuation
-
2022
- 2022-03-31 CY CY20221100250T patent/CY1125103T1/el unknown
- 2022-06-30 FR FR22C1033C patent/FR22C1033I1/fr active Active
- 2022-07-28 HU HUS2200036C patent/HUS2200036I1/hu unknown